Angiotensin II and vascular inflammation

Medical Science Monitor

Volumn 11, Issue 6, 2005, Pages

  Cheng, Zhong Jian ^a   Vapaatalo, Heikki ^a   Mervaala, Eero ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Angiotensin II; Angiotensin II receptors; Angiotensin converting enzyme; Leukocyte infiltration; Nuclear transcription factor NF B; Reactive oxygen species; Renin angiotensinsystem

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CHEMOKINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; EPOXYICOSATRIENOIC ACID; FURANONE DERIVATIVE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSIGLITAZONE; SELECTIN; STATINE DERIVATIVE; SULINDAC; VALSARTAN;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL WALL; CELL PROLIFERATION; DIABETIC ANGIOPATHY; FIBROSIS; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; HYPERTENSION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATION REDUCTION REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE; UPREGULATION; VASCULITIS;

ANGIOTENSIN II; ANIMALS; BLOOD VESSELS; CAPILLARY PERMEABILITY; CYCLOOXYGENASE 2; ENDOTHELIN-1; HUMANS; INFLAMMATION; MEMBRANE PROTEINS; NITRIC OXIDE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SIGNAL TRANSDUCTION;

EID: 21344463983     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (184)

1. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res, 2000; 80: 494-501
2. Alexander RW: Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension, 1995; 25: 155-61
3. Mervaala E, Muller DN, Schmidt F et al: Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension, 2000; 35: 587-94
4. Burnier M, Brunner HR: Angiotensin II receptor antagonists. Lancet, 2000; 19(355): 637-45
5. Takai S, Kim S, Sakonjo H, Miyazaki M: Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholesterol diet. J Hypertens, 2003; 21: 361-69
6. Chen HJ, Li DY, Saldeen T et al: Attenuation of tissue P-selectin and MCP-1 expression and intimal proliferation by AT(1) receptor blockade in hyperlipidemic rabbits. Biochem Biophys Res Commun, 2001; 282: 474-79
7. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS: Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation, 2001; 104: 1985-91
8. Mervaala EM, Muller DN, Park JK et al: Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension, 1999; 33: 389-95
9. Cheng ZJ, Vaskonen T, Tikkanen I et al: Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension, 2001; 37: 433-39
10. Cheng ZJ, Finckenberg P, Louhelainen M et al: Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27). Eur J Pharmacol, 2003; 461: 159-69
11. Campbell DJ: Circulating and tissue angiotensin systems. J Clin Invest, 1987; 79: 1-6
12. Johnston CI: Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens Suppl, 1992; 10: S13-S26
13. Gibbons GH, Dzau VJ: The emerging concept of vascular remodeling. N Engl J Med, 1994; 19: 1431-38
14. Padmanabhan N, Jardine AG, McGrath JC, Connell JM: Angiotensin-converting enzyme-independent contraction to angiotensin I in human resistance arteries. Circulation, 1999; 99: 2914-20
15. Hollenberg NK, Fisher ND, Price DA: Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension, 1998; 32: 387-92
16. Petrie MC, Padmanabhan N, McDonald JE et al: Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol, 2001; 37: 1056-61
17. Okunishi H, Oka Y, Shiota N et al: Marked species-difference in the vascular angiolensin II-forming pathways: humans versus rodents. Jpn J Pharmacol, 1993; 62: 207-10
18. Bader M, Peters J, Baltatu O et al: Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med, 2001; 79: 76-102
19. Shimizu A, Yamagata T, Tatsuno H et al: Radio-frequency catheter ablation therapy in elderly patients with supraventricular tachycardia. Nippon Ronen Igakkai Zasshi, 1998; 35: 451-57
20. de Gasparo M, Catt KJ, Inagami T et al: International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev, 2000; 52: 415-72
21. Kakar SS, Sellers JC, Devor DC et al: Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. Biochem Biophys Res Commun, 1992; 183: 1090-96
22. Dinh DT, Frauman AG, Johnston CI, Fabiani ME: Angiotensin receptors: distribution, signalling and function. Clin Sci (Lond), 2001; 100: 481-92
23. Romero JC, Reckelhoff JF: State-of-the-Art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension, 1999; 34: 943-49
24. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M: Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol, 2000; 20: 2175-83
25. Mervaala E, Dehmel B, Gross V et al: Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes. J Am Soc Nephrol, 1999; 10: 1669-80
26. Kiarash A, Pagano PJ, Tayeh M et al: Upregulated expression of rat heart intercellular adhesion molecule-1 in angiotensin II- but not phenylephrine-induced hypertension. Hypertension, 2001; 37: 58-65
27. Morrissey JJ, Klahr S: Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol, 1998; 274: F580-F586
28. Wu L, Iwai M, Nakagami H et al: Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular-injury. Circulation, 2001; 104: 2716-21
29. Ruiz-Oriega M, Lorenzo O, Ruperez M et al: Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension, 2001; 38: 1382-87
30. Wright JW, Krebs LT, Stobb JW, Harding JW: The angiotensin IV system: functional implications. Front Neuroendocrinol, 1995; 16: 23-52
31. Ardaillou R: Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. Curr Opin Nephrol Hypertens, 1997; 6: 28-34
32. Suzuki Y, Ruiz-Ortega M, Lorenzo O et al: Inflammation and angiotensin II. Int J Biochem Cell Biol, 2003; 35: 881-900
33. Victorino GP, Newton CR, Curran B: Effect of angiotensin II on microvascular permeability. J Surg Res, 2002; 104: 77-81
34. Alvarez A, Cerda-Nicolas M, Naim Abu NY et al: Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood, 2004; 104: 402-8
35. Kim JA, Berliner JA, Nadler JL: Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun, 1996; 226: 862-68
36. Krejcy K, Eichler HG, Jilma B et al: Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo. Can J Physiol Pharmacol, 1996; 74: 9-14
37. Tayeh MA, Scicli AG: Angiotensin II and bradykinin regulate the expression of P-selectin on the surface of endothelial cells in culture. Proc Assoc Am Physicians, 1998; 110: 412-21
38. Tummala PE, Chen XL, Sundell CL et al: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation, 1999; 100: 1223-29
39. Carlos TM, Harlan JM: Leukocyte-endothelial adhesion molecules. Blood, 1994; 84: 2068-101
40. Riaz AA, Wang Y, Schramm R et al: Role of angiotensin II in ischemia/ reperfusion-induced lenkocyte-endothelium interactions in the colon. Faseb J, 2004; 18: 881-83
41. Piqueras L, Kubes P, Alvarez A et al: Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation. Circulation, 2000; 102: 2118-23
42. Grafe M, Auch-Schwelk W, Zakrzewicz A et al: Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res, 1997; 81: 804-11
43. Haught WH, Mansour M, Rothlein R et al: Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. Am Heart J, 1996; 132: 1-8
44. Albertini JP, Valensi P, Lormeau B et al: Soluble L-selectin level is a marker for coronary artery disease in type 2 diabetic patients. Diabetes Care, 1999; 22: 2044-48
45. Prasad A, Koh KK, Schenke WH et al: Role of angiotensin II type I receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am Heart J, 2001; 142: 248-53
46. Pueyo ME, Gonzalez W, Nicoletti A et al: Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol, 2000; 20: 645-51
47. Pastore L, Tessitore A, Martinotti S et al: Angiotensin II stimulates intercellular adhesion molecule-I (ICAM-I) expression by human vascular endothelial cells and increases soluble ICAM-1 release in invo. Circulation, 1999; 100: 1646-52
48. Diep QN, El Mabrouk M, Cohn JS et al: Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation, 2002; 105: 2296-302
49. Muller DN, Mervaala EM, Schmidt F et al: Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension, 2000; 36: 282-90
50. Ruiz-Ortega M, Ruperez M, Lorenzo O et al: Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl, 2002; 12-22
51. Ni W, Kitamoto S, Ishibashi M et al: Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angioiensin II-induced progression of established atherosclerosis in hyperchotesterolemic mice. Arterioscler Thromb Vasc Biol, 2004; 24: 534-39
52. Chen XL, Tummala PE, Olbrych MT et al: Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res, 1998; 83: 952-59
53. Ruiz-Ortega M, Lorenzo O, Egido J: Angiotensin III increases MCP-1 and activates NF-kappaB and AP-1 in cultured mesangial and mononuclear cells. Kidney Int, 2000; 57: 2285-98
54. Kranzhofer R, Schmidt J, Pfeiffer CA et al: Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 1999; 19: 1623-29
55. Hayashidani S, Tsutsui H, Shiomi T et al: Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation, 2003; 108: 2134-40
56. Martin G, Dol F, Mares AM et al: Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan. J Cardiovasc Pharmacol, 2004; 43: 191-99
57. Soejima H, Ogawa H, Yasue H et al: Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J Am Coll Cardiol, 1999; 34: 983-88
58. Proudfoot JM, Croft KD, Puddey IB, Beilin LJ: Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1. J Pharmacol Exp Ther, 2003; 305: 846-53
59. Dol F, Martin G, Staels B et al: Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol, 2001; 38: 395-405
60. Gerszten RE, Garcia-Zepeda EA, Lim YC et al: MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature, 1999; 398: 718-23
61. Ito T, Ikeda U, Yamamoto K, Shimada K: Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells. Atherosclerosis, 2002; 165: 51-55
62. Nomura S, Shouzu A, Omoto S et al: Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus. Clin Appl Thromb Hemost, 2004; 10: 133-41
63. Ishibashi M, Egashira K, Zhao Q et al: Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol, 2004; 24: 174-78
64. Bush E, Maeda N, Kuziel WA et al: CC chemokine receptor 2 is required for macrophage infiltration and vascular hypertrophy in angiotensin II-induced hypertension. Hypertension, 2000; 36: 360-63
65. Wolf G, Ziyadeh FN, Thaiss F et al: Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest, 1997; 100: 1047-58
66. Benigni A, Remuzzi G: How renal cytokines and growth factors contribute to renal disease progression. Am J Kidney Dis, 2001; 37: S21-S24
67. Rimarachin JA, Jacobson JA, Szabo P et al: Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb, 1994; 14: 1021-31
68. deBlois D, Lombardi DM, Su EJ et al: Angiotensin II induction of osteopontin expression and DNA replication in rat arteries. Hypertension, 1996; 28: 1055-63
69. Bruemmer D, Collins AR, Noh G et al: Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest, 2003; 112: 1318-31
70. Ikeda U, Ikeda M, Seino Y et al: Expression of intercellular adhesion molecule-1 on ral vascular smooth muscle cells by pro-inflammatory cytokines. Atherosclerosis, 1993; 104: 61-68
71. Kishimoto T, Akira S, Narazaki M, Taga T: Interleukin-6 family of cytokines and gpI30. Blood, 1995; 86: 1243-54
72. Mantovani A: The interplay between primary and secondary cytokines. Cytokines involved in the regulation of monocyte recruitment. Drugs, 1997; 54(Suppl. 1): 15-23
73. Biswas P, Delfanti F, Bernasconi S et al: Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood, 1998; 91: 258-65
74. Han Y, Runge MS, Brasier AR: Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res, 1999; 84: 695-703
75. Arai M, Wada A, Isaka Y et al: In vivo transfection of genes for renin and angiotensinogen into the glomerular cells induced phenotypic change of the mesangial cells and glomerular sclerosis. Biochem Biophys Res Commun, 1995; 206: 525-32
76. Mervaala E, Muller DN, Park JK et al: Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes. Hypertension, 2000; 35(1 Pt 2): 360-66
77. Schieffer B, Schieffer E, Hilfiker-Kleiner D et al: Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation, 2000; 101: 1372-78
78. Brasier AR, Recinos A III, Eledrisi MS: Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol, 2002; 22: 1257-66
79. Dorffel Y, Latsch C, Stuhlmuller B et al: Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension, 1999; 34: 113-17
80. Strukova SM: Thrombin as a regulator of inflammation and reparative processes in tissues. Biochemistiy (Mosc), 2001; 66: 8-18
81. Blann AD, Nadar S, Lip GY: Pharmacological modulation of platelet function in hypertension. Hypertension, 2003; 42: 1-7
82. James IM, Dickenson EJ, Burgoyne W et al: Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation. J Hum Hypertens, 1988; 2: 21-25
83. 2+] by platelets from hypertensive diabetic patients. Br J Clin Pharmacol, 1992; 33: 161-65
84. Lopez-Farre A, Sanchez dM, Monton M et al: Angiotensin II AT(1) receptor antagonists and platelet activation. Nephrol Dial Transplant, 2001; 16(Suppl. 1): 45-49
85. Tsutamoto T, Wada A, Maeda K et al: Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol, 2000; 35: 714-21
86. Johnson RJ, Alpers CE, Yoshimura A et al: Renal injury from angiotensin II-medialed hypertension. Hypertension, 1992; 19: 464-74
87. Wolf G, Wenzel UO: Angiotensin II and Cell Cycle Regulation. Hypertension, 2004; 43: 693-98
88. Cottone S, Vadala A, Vella MC et al: Changes of plasma endothelin and growth factor levels, and of left ventricular mass, after chronic AT1-receptor blockade in human hypertension. Am J Hypertens, 1998; 11: 548-53
89. Wong J, Rauhoft C, Dilley RJ et al: Angiotensin-converting enzyme inhibition abolishes medial smooth muscle PDGF-AB biosynthesis and attenuates cell proliferation in injured carotid arteries: relationships to neointima formation. Circulation, 1997; 96: 1631-40
90. Su EJ, Lombardi DM, Wiener J et al: Mitogenic effect of angiotensin II on rat carotid arteries and type II or III mesenteric microvessels but not type I inesenteric microvessels is mediated by endogenous basic fibroblast growth factor. Circ Res, 1998; 82: 321-27
91. Chua CC, Hamdy RC, Chua BH: Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta, 1998; 1401: 187-94
92. Otani A, Takagi H, Suzuma K, Honda Y: Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res, 1998; 82: 619-28
93. Wolf G, Mueller E, Stahl RA, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured marine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest, 1993; 92: 1366-72
94. Finckenberg P, Inkinen K, Ahonen J et al: Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. Am J Pathol, 2003; 163: 355-66
95. Ruperez M, Ruiz-Ortega M, Esteban V et al: Angiotensin II increases connective tissue growth factor in the kidney. Am J Pathol, 2003; 163: 1937-47
96. Ruperez M, Lorenzo O, Blanco-Colio LM et al: Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation, 2003; 108: 1499-505
97. Dandona P, Kumar V, Aljada A et al: Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab, 2003; 88: 4496-501
98. Akgur FM, Brown MF, Zibari GB et al: Role of superoxide in hemorrhagic shock-induced P-selectin expression. Am J Physiol Heart Circ Physiol, 2000; 279: H791-H797
99. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res, 2000; 87: 840-44
100. Fleming I: Cytochrome p450 and vascular homeostasis. Circ Res, 2001; 89: 753-62
101. Napoli C, de Nigris F, Palinski W: Multiple role of reactive oxygen species in the arterial wall. J Cell Biochem, 2001; 82: 674-82
102. Griendling KK, Ushio-Fukai M: Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept, 2000; 91: 21-27
103. Griendling KK, Minien CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res, 1994; 74: 1141-48
104. Rajagopalan S, Kurz S, Munzel T et al: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest, 1996; 97: 1916-23
105. Seshiah PN, Weber DS, Rocic P et al: Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res, 2002; 91: 406-13
106. Touyz RM, Schiffrin EL: Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens, 2001; 19: 1245-54
107. Mollnau H, Wendt M, Szocs K et al: Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res, 2002; 90: E58-E65
108. Laursen JB, Rajagopalan S, Galis Z et al: Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation, 1997; 95: 588-93
109. Liu J, Yang F, Yang XP et al: NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol, 2003; 23: 776-82
110. Ortiz MC, Manriquez MC, Romero JC, Juncos LA: Antioxidants block angiotensin II-induced increases in blood pressure and endothelin. Hypertension, 2001; 38: 655-59
111. Ogihara T, Asano T, Ando K et al: Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension, 2002; 40: 872-79
112. Mervaala E, Finckenberg P, Lapatto R et al: Lipoic acid supplementation prevents angiotensin II-induced renal injury. Kidney Int, 2003; 64: 501-8
113. Helkamaa T, Finckenberg P, Louhelainen M et al: Entacapone protects from angiotensin II-induced inflammation and renal injury. J Hypertens, 2003; 21: 2353-63
114. Park JK, Muller DN, Mervaala EM et al: Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int, 2000; 58: 1420-30
115. Dechend R, Fiebler A, Lindschau C et al: Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. Am J Hypertens, 2001; 14: S55-S61
116. Dechend R, Fiebeler A, Park JK et al: Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation, 2001; 104: 576-81
117. Touyz RM, Berry C: Recent advances in angiotensin II signaling. Braz J Med Biol Res, 2002; 35: 1001-15
118. Khan BV, Harrison DG, Olbrych MT et al: Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA, 1996; 93: 9114-19
119. Barnes PJ, Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med, 1997; 336: 1066-71
120. Ruiz-Ortega M, Lorenzo O, Ruperez M et al: Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors. Am J Pathol, 2001; 158: 1743-56
121. Muller DN, Heissmeyer V, Dechend R et al: Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage. Faseb J, 2001; 15: 1822-24
122. Costanzo A, Moretti F, Burgio VL et al: Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol, 2003; 195: 402-10
123. Jiang B, Xu S, Hou X et al: Angiotensin II differentially regulates interleukin-1-beta-inducible NO synthase (iNOS) and vascular cell adhesion molecule-1 (VCAM-1) expression: role of p38 MAPK. J Biol Chem, 2004; 279: 20363-68
124. Muller DN, Dechend R, Mervaala EM et al: NF-kappaB inhibition amelio-rates angiotensin II-induced inflammatory damage in rats. Hypertension, 2000; 35: 193-201
125. Muller DN, Mervaala EM, Dechend R et al: Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am J Pathol, 2000; 157: 111-22
126. Lee MH, Kim E, Kim TS: Exposure to 4-tert-octylphenol, an environmentally persistent alkylphenol, enhances interleukin-4 production in T cells via NF-AT activation. Toxicol Appl Pharmacol, 2004; 197: 19-28
127. Delerive P, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol, 2001; 169: 453-59
128. Collin M, Patel NS, Dugo L, Thiemermann C: Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglaudin J2 against the multiple organ failure caused by endotoxin. Crit Care Med, 2004; 32: 826-31
129. Tham DM, Martin-McNulty B, Wang YX et al: Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics, 2002; 11: 21-30
130. Delerive P, De Bosscher K, Besnard S et al: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem, 1999; 274: 32048-54
131. Marx N, Sukhova GK, Collins T et al: PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation, 1999; 99: 3125-31
132. Staels B, Koenig W, Habib A et al: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature, 1998; 393: 790-93
133. Tham DM, Wang YX, Rutledge JC: Modulation of vascular inflammation by PPARs. Drug News Perspect, 2003; 16: 109-16
134. Diep QN, Amiri F, Tonyz RM et al: PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension, 2002; 40: 866-71
135. Mohanty P, Aljada A, Ghanim H et al: Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab, 2004; 89: 2728-35
136. Napoli C, Ignarro LJ: Nitric oxide and atherosclerosis. Nitric Oxide, 2001; 5: 88-97
137. Miles AM, Bohle DS, Glassbrenner PA et al: Modulation of superoxide-dependent oxidation and hydroxylation reactions by nitric oxide. J Biol Chem, 1996; 271: 40-47
138. Beckman JS, Beckman TW, Chen J et al: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA, 1990; 87: 1620-24
139. Paton JF, Deuchars J, Ahmad Z et al: Adenoviral vector demonstrates that angiotensin II-induced depression of the cardiac baroreflex is mediated by endothelial nitric oxide synthase in the nucleus tractus solitarü of the rat. J Physiol, 2001; 531: 445-58
140. Park JK, Fiebeler A, Muller DN et al: Lacidipine inhibits adhesion molecule and oxidase expression independent of blood pressure reduction in angiotensin-induced vascular injury. Hypertension, 2002; 39: 685-89
141. Mervaala EM, Cheng ZJ, Tikkanen I et al: Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension, 2001; 37: 414-18
142. Zhou MS, Jaimes EA, Raij L: Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats. Am J Hypertens, 2004; 17: 167-71
143. Wattanapitayakul SK, Weinstein DM, Holycross BJ, Bauer JA: Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. Faseb J, 2000; 14: 271-78
144. Nithipatikom K, Holmes BB, McCoy MJ et al: Chronic administration of nitric oxide reduces angiotension II receptor type I expression and aldosterone synthesis in zona glomerulosa cells. Am J Physiol Endocrinol Metab, 2004; 287: 820-27
145. Vandermeersch S, Stefanovic V, Hus-Citharet A et al: AT1 receptor expression in glomeruli from NO-deficient rats. Nephron Exp Nephrol, 2003; 95: E119-E128
146. Chen R, Iwai M, Wu L et al: Important rote of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury. Hypertension, 2003; 42: 542-47
147. Tamarat R, Silvestre JS, Durie M, Levy BI; Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest, 2002; 82: 747-56
148. Marceau F: Kinin B1 receptors: a review. Immunopharmacology, 1995; 30: 1-26
149. Coelho MM, Oliveira CR, Pajolla GP et al: Central involvement of kinin B1 and B2 receptors in the febrile response induced by endotoxin in rats. Br J Pharmacol, 1997; 121: 296-302
150. Gohlke P, Linz W, Scholkens BA et al: Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension, 1994; 23: 411-18
151. Regoli D, Barabe J: Pharmacology of bradykinin and related kinins. Pharmacol Rev, 1980; 32: 1-46
152. Schanstra JP, Marin-Castano ME, Praddaude F et al: Bradykinin B(I) receptor-mediated changes in renal hemodynamics during endotoxin-induced inflammation. J Am Soc Nephrol, 2000; 11: 1208-15
153. Cervenka L, Vaneckova I, Maly J et al: Genetic inactivation of the B2 receptor in mice worsens two-kidney, one-clip hypertension: role of NO and the AT2 receptor. J Hypertens, 2003; 21: 1531-38
154. Tsutsumi Y, Matsubara H, Masaki H et al: Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest, 1999; 104: 925-35
155. Kintsurashvili E, Duka I, Gavras I et al: Effects of ANG II on bradykinin receptor gene expression in cardiomyocytes and vascular smooth muscle cells. Am J Physiol Heart Circ Physiol, 2001; 281: H1778-H1783
156. Harris RC: Cyclooxygenase-2 in the kidney. J Am Soc Nephrol, 2000; 11: 2387-94
157. Breyer MD, Harris RC: Cyclooxygenase 2 and the kidney. Curr Opin Nephrol Hypertens, 2001; 10: 89-98
158. Kuwano T, Nakao S, Yamamoto H et al: Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. Faseb J, 2004; 18: 300-10
159. Schwab JM, Schluesener HJ, Meyermann R, Serhan CN: COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics? Prostaglandins Lenkot Essent Fatty Acids, 2003; 69: 339-43
160. Schmedtje JF Jr, Ji YS, Liu WL et al: Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem, 1997; 272: 601-8
161. Kramer C, Sunkomat J, Witte J et al: Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res, 2002; 90: 770-76
162. Rocha R, Martin-Berger CL, Yang P et al: Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology, 2002; 143: 4828-36
163. Torre-Amione G, Kapadia S, Lee J et al: Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation, 1996; 93: 704-11
164. Wong SC, Fukuchi M, Melnyk P et al: Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation, 1998; 98: 100-3
165. Ohnaka K, Numaguchi K, Yamakawa T, Inagami T: Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension, 2000; 35: 68-75
166. Cheng HF, Wang JL, Zhang MZ et al: Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest, 1999; 103: 953-61
167. Wolf K, Castrop H, Hartner A et al: Inhibition of the renin-angiotensin system upregulates cyclooxygenase-2 expression in the macula densa. Hypertension, 1999; 34: 503-7
168. Schiffrin EL: Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens, 2001; 14: S83-S89
169. Duerrschmidt N, Wippich N, Goettsch W et al: Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun, 2000; 269: 713-17
170. Luft FC, Mervaala E, Muller DN et al: Hypertension-induced end-organ damage: A new transgenic approach to an old problem. Hypertension, 1999; 33: 212-18
171. Browatzki M, Schmidt J, Kubler W, Kranzhofer R: Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Basic Res Cardiol, 2000; 95: 98-105
172. Kuchan MJ, Frangos JA: Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am J Physiol, 1993; 264: H150-H156
173. Luscher TF, Noll G: The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis, 1995; 118(Suppl.): S81-S90
174. Haynes WG, Webb DJ: Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens, 1998; 16: 1081-98
175. Imai T, Hirata Y, Emori T et al: Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension, 1992; 19: 753-57
176. Crawford DC, Chobanian AV, Brecher P: Angiotensin II induces fibronectin
177. Sung CP, Arleth AJ, Storer BL, Ohlstein EH: Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther, 1994; 271: 429-37
178. Rajagopalan S, Laursen JB, Borthayre A et al: Role for endothelin-1 in angiotensin II-mediated hypertension. Hypertension, 1997; 30: 29-34
179. Moreau P, d'Uscio LV, Shaw S et al: Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation, 1997; 96: 1595-97
180. Rossi GP, Sacchetto A, Rizzoni D et al: Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms. Arterioscler Thromb Vasc Biol, 2000; 20: 949-56
181. Fisslthaler B, Popp R, Kiss L et al: Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature, 1999; 401: 493-97
182. Node K, Huo Y, Ruan X et al: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids, Science, 1999; 285: 1276-79
183. Carcillo JA, Korzekwa KR, Jones GS et al: The cytochrome P450 suicide inhibitor, 1-aminobenzotriazole, sensitizes rats to zymosan-induced toxicity. Res Commun Mol Pathol Pharmacol, 1998; 102: 57-68
184. Kaergel E, Muller DN, Honeck H et al: P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. Hypertension, 2002; 40: 273-79